Quantcast
Last updated on April 18, 2014 at 12:48 EDT

Latest gout Stories

2011-05-02 12:32:08

The incidence of gout is on the rise and duel energy CT has the potential to allow non-invasive diagnosis of the disease, according to radiologists at the University of British Columbia, Vancouver General Hospital, in Vancouver, BC. Gout is caused by the deposition of monosodium urate (MSU) monohydrate crystals that stimulate acute episodes of inflammation. Chronic tophaceous gout often presents as juxtarticular soft-tissue masses, distinct erosions, overhanging bony margins, and thickening...

2011-04-28 15:05:00

EAST BRUNSWICK, N.J., April 28, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that three abstracts will be presented at the European League Against Rheumatism (EULAR) 2011 Annual Congress. The conference will take place on May 25 - 28 in London, United Kingdom, and will feature the abstracts as two oral presentations and one poster presentation. The first scheduled oral presentation and the poster session will address the prevalence of gout in Europe...

2011-04-28 00:00:28

The Concept Laboratories arthritis and gout treatment story is actually three amazing stories in one. (1) Capsaicin medical research (2) Advanced nanotechology pain relief ingredient delivery (3) Introduction of the first timed-release topical pain relief brand, MyOmega 3 (http://www.gouttreatment.ultimizer.com) Chicago, IL (PRWEB) April 27, 2011 For the estimated 27 million Americans who suffer from osteoarthritis and gout, a new OTC pain relief treatment is now available direct from the...

2011-04-25 08:00:00

SAN DIEGO, April 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that additional data from its completed Phase 2b study (Study 203) evaluating lesinurad in combination with allopurinol in gout patients not adequately responding to allopurinol alone will be presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) on May 26, 2011 in London, UK. The Company will also present additional data from a...

2011-04-13 13:32:07

Tart cherries may reduce inflammation, risk factors for heart disease Tart cherries have a unique combination of powerful antioxidants that may help reduce risk factors for heart disease, according to new research presented at the Experimental Biology annual meeting in Washington, DC. In a series of three studies, researchers from University of Michigan, University of Arizona and Brunswick labs studied the antioxidant levels and anti-inflammatory benefits of tart cherries. They found:...

2011-04-12 08:15:00

WASHINGTON, April 12, 2011 /PRNewswire/ -- Tart cherries have a unique combination of powerful antioxidants that may help reduce risk factors for heart disease, according to new research presented at the Experimental Biology annual meeting in Washington, DC. In a series of three studies, researchers from University of Michigan, University of Arizona and Brunswick labs studied the antioxidant levels and anti-inflammatory benefits of tart cherries. They found: Reduced Inflammation and...

2011-04-06 09:15:00

SAN DIEGO, April 6, 2011 /PRNewswire/ -- Getting the word out about preventing and treating gouty arthritis has new urgency with the number of Americans suffering from this form of arthritis now topping the 8 million mark. If left untreated, gout can be disabling. Gout is also associated with other serious health conditions, making it a complex diagnosis and treatment challenge for physicians. In addition to the core patient demographic of men age 40 plus, post-menopausal women are at...

2011-03-11 07:30:00

SAN DIEGO, March 11, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and announced fourth quarter and full-year 2010 financial results. "With approximately $160 million in cash as of the end of February, we are in an excellent financial position," commented Barry D. Quart, PharmD, Ardea's president and chief executive...

2011-02-28 06:30:00

TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period. Patients who received ARCALYST at a weekly, self-administered, subcutaneous dose of either 160 milligrams (mg) or 80...

2011-02-17 06:00:00

TARRYTOWN, N.Y., Feb. 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the full year and fourth quarter of 2010 and provided an update on development programs and upcoming milestones. "2010 was a very productive year for Regeneron as we reported positive Phase 3 results in four clinical trials: two with VEGF Trap-Eye in wet age-related macular degeneration, called wet AMD, one with VEGF Trap-Eye in central retinal vein...